Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 1689 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1
Md. Akil Hossain,Rokeya Pervin
.2018;()455
[DOI]
2The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
Anne Řrgaard,Jens J. Holst
Diabetologia.2017;60(9)1731
[DOI]
3Clinical Characteristics and Satisfaction of Liraglutide Treatment among Patients with Type 2 Diabetes: A Prospective Study
Ayman A Al Hayek,Asirvatham A Robert,Mohamed A Al Dawish
Clinical Medicine Insights: Endocrinology and Diabetes.2019;12(9)117955141983493
[DOI]
4GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
Andrei C. Sposito,Otávio Berwanger,Luiz Sérgio F. de Carvalho,José Francisco Kerr Saraiva
Cardiovascular Diabetology.2018;17(1)117955141983493
[DOI]
5CoMFA, CoMSIA and HQSAR Analysis of 3-aryl-3-ethoxypropanoic Acid Derivatives as GPR40 Modulators
Krishna A. Gajjar,Anuradha K. Gajjar
Current Drug Discovery Technologies.2020;17(1)100
[DOI]
6Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
Leigh Perreault,Helena Rodbard,Virginia Valentine,Eric Johnson
Advances in Therapy.2019;36(2)265
[DOI]
7Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
Juergen Sandow
Advances in Therapy.2020;36(2)1
[DOI]
8RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Rajeev Chawla,S. V. Madhu,B. M. Makkar,Sujoy Ghosh,Banshi Saboo,Sanjay Kalra
International Journal of Diabetes in Developing Countries.2020;40(S1)1
[DOI]
9A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
Neil Webb,Michelle Orme,Michal Witkowski,Rie Nakanishi,Jakob Langer
Diabetes Therapy.2018;9(3)973
[DOI]
10A Systematic Review on Anti-diabetic Properties of Chalcones
Sonia Rocha,Daniela Ribeiro,Eduarda Fernandes,Marisa Freitas
Current Medicinal Chemistry.2020;27(14)2257
[DOI]
11Effect of semaglutide on coronary atherosclerosis progression in patients with type II diabetes
Sajad Hamal,Lavanya Cherukuri,Kashif Shaikh,April Kinninger,Jay Doshi,Divya Birudaraju,Matthew J. Budoff
Coronary Artery Disease.2020;31(3)306
[DOI]
12Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
Julio Rosenstock,Christopher H. Sorli,Michael E. Trautmann,Cristóbal Morales,Ulrich Wendisch,George Dailey,Marcus Hompesch,In Young Choi,Jahoon Kang,John Stewart,Kun-Ho Yoon
Diabetes Care.2019;42(9)1733
[DOI]
13A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Irene Romera,Ana Cebrián-Cuenca,Fernando Álvarez-Guisasola,Fernando Gomez-Peralta,Jesús Reviriego
Diabetes Therapy.2019;10(1)5
[DOI]
14Lixisenatide: A New Option for Managing Type 2 Diabetes
Jonathan S. Newsome
Journal of Pharmacy Technology.2017;33(5)195
[DOI]
15Selective beneficial cardiometabolic effects of vertical sleeve gastrectomy are predominantly mediated through glucagon-like peptide (GLP-1) in Zucker diabetic fatty rats
Sunil Kumar,Raymond Lau,Thomas Palaia,Christopher Hall,Jenny Lee,Keneth Hall,Collin E. Brathwaite,Louis Ragolia
Annals of Medicine and Surgery.2016;12(5)65
[DOI]
16Long-lasting Glucagon-like Peptide 1 Analogue Exendin-4 Ameliorates the Secretory and Synthetic Function of Islets Isolated From Severely Scalded Rats
Dongxu Zhao,Li Ma,Chuanan Shen,Dawei Li,Wenfeng Cheng,Yuru Shang,Zhaoxing Liu,Xin Wang,Kai Yin
Journal of Burn Care & Research.2018;39(4)545
[DOI]
17GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis
Marco Castellana,Angelo Cignarelli,Francesco Brescia,Luigi Laviola,Francesco Giorgino
Diabetes/Metabolism Research and Reviews.2019;35(1)e3082
[DOI]
18Narrative review of the effects of antidiabetic drugs on albuminuria
Habib Yaribeygi,Stephen L. Atkin,Niki Katsiki,Amirhossein Sahebkar
Journal of Cellular Physiology.2019;234(5)5786
[DOI]
19Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
Sanjay Kalra,Ashok Kumar Das,Rakesh Kumar Sahay,Manash Pratim Baruah,Mangesh Tiwaskar,Sambit Das,Sudip Chatterjee,Banshi Saboo,Ganapathi Bantwal,Saptarshi Bhattacharya,Gagan Priya,Manoj Chawla,Kiraninder Brar,Syed Abbas Raza,Azizul Hasan Aamir,Dina Shrestha,Noel Somasundaram,Prasad Katulanda,Faria Afsana,Shahjada Selim,Mohammad Wali Naseri,Ali Latheef,Manilka Sumanatilleke
Diabetes Therapy.2019;10(5)1645
[DOI]
20Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients
Lima Lawrence,Venu Menon,Sangeeta Kashyap
Current Cardiology Reports.2018;20(8)1645
[DOI]
21A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
Sanjay Kalra,Rakesh Sahay
Diabetes Therapy.2020;11(9)1965
[DOI]
22Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
Dongzhe Hong,Lei Si,Minghuan Jiang,Hui Shao,Wai-kit Ming,Yingnan Zhao,Yan Li,Lizheng Shi
PharmacoEconomics.2019;11(9)1965
[DOI]
23Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
Sebastian Niezen,Humberto Diaz del Castillo,Lumen A. Mendez Castaner,Alessia Fornoni
Endocrinology, Diabetes & Metabolism.2019;2(3)1965
[DOI]
24Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
Marco Castellana,Angelo Cignarelli,Francesco Brescia,Sebastio Perrini,Annalisa Natalicchio,Luigi Laviola,Francesco Giorgino
Scientific Reports.2019;9(1)1965
[DOI]
25The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy
Jerry Meece
Advances in Therapy.2017;34(3)638
[DOI]
26The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy
Juergen Sandow
Advances in Therapy.2020;34(3)243
[DOI]
27Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy
Philip D. Home,Bo Ahrén,Jane E.B. Reusch,Marc Rendell,Peter N. Weissman,Deborah T. Cirkel,Diane Miller,Philip Ambery,Molly C. Carr,Michael A. Nauck
Diabetes Research and Clinical Practice.2017;131(3)49
[DOI]
28Body Weight Considerations in the Management of Type 2 Diabetes
Caroline M. Apovian,Jennifer Okemah,Patrick M. O’Neil
Advances in Therapy.2019;36(1)44
[DOI]
29Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
Ying Liu,Xia Jiang,Xin Chen
Lipids in Health and Disease.2017;16(1)44
[DOI]
30GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective
Roy Rasalam,John Barlow,Mark Kennedy,Pat Phillips,Alan Wright
Diabetes Therapy.2019;10(4)1205
[DOI]
31Emerging technologies to achieve oral delivery of GLP-1 and GLP-1 analogs for treatment of type 2 diabetes mellitus (T2DM)
Shengwu Ma,Liang We,Hongji Yang,Shaoping Deng,Anthony M. Jevnikar
Canadian Journal of Biotechnology.2017;1(1)1
[DOI]
32Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
M.S. Capehorn,A.-M. Catarig,J.K. Furberg,A. Janez,H.C. Price,S. Tadayon,B. Vergčs,M. Marre
Diabetes & Metabolism.2020;46(2)100
[DOI]
33Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes
Kun-Ho Yoon,Jahoon Kang,Se Chang Kwon,Michael E. Trautmann,Marcus Hompesch,John Stewart,Christopher H. Sorli
Diabetes, Obesity and Metabolism.2020;22(8)1292
[DOI]
34The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease
Carlota Recio,Francesco Maione,Asif J. Iqbal,Nicola Mascolo,Vincenzo De Feo
Frontiers in Pharmacology.2017;7(8)1292
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal